Current Report Filing (8-k)
05 Juni 2013 - 5:51PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of
The Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): |
June 5, 2013 |
|
Arch Therapeutics, Inc. |
(Exact name of registrant as specified in its charter) |
|
Nevada |
333-178883 |
46-0524102 |
(State or other jurisdiction |
(Commission |
(IRS Employer |
of incorporation) |
File Number) |
Identification No.) |
|
|
|
Pembroke House, 28-32 Pembroke St Upper, Dublin 2, Ireland |
(Address of principal executive offices) (zip code) |
|
Registrant’s telephone number, including area code: |
353-871536401 |
|
|
Almah, Inc. |
(Former name or former address, if changed since last report.) |
|
|
|
|
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
o Written communications
pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material
pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Item 5.03 Amendments to Articles of Incorporation or Bylaws;
Change in Fiscal Year.
In connection with Almah, Inc.’s
(the “Company”) receipt of approval from the Financial Industry Regulatory Authority (“FINRA”), effective
June 5, 2013, the Company amended its Articles of Incorporation to change its name from “Almah, Inc.” to “Arch
Therapeutics, Inc.” (the “Name Change”).
The full text of the Certificate of Amendment
to Articles of Incorporation giving effect to the Name Change is included as Exhibit 3.1 hereto and incorporated herein by reference.
Item 8.01 Other Events.
In connection with the Name Change described
in Item 5.03 above, FINRA assigned the Company a new stock symbol, “ARTH”. This new symbol took effect at the open
of business on June 5, 2013.
Item 9.01 Financial Statements and
Exhibits.
Exhibit No. |
Exhibit Description |
|
|
3.1
|
Certificate of Amendment to Articles of Incorporation |
SIGNATURE
Pursuant to the requirements
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
hereunto duly authorized.
|
ARCH THERAPEUTICS, INC. |
|
|
|
|
|
|
Dated: June 5, 2013 |
/s/ Terrence W. Norchi, M.D. |
|
Terrence W. Norchi, M.D. |
|
President, Chief Executive Officer and |
|
Interim Chief Financial Officer |
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jun 2024 bis Jul 2024
Arch Therapeutics (QB) (USOTC:ARTH)
Historical Stock Chart
Von Jul 2023 bis Jul 2024